Evenepoel P
Department of Medicine, Division of Nephrology, University Hospital Leuven, Leuven, Belgium.
Kidney Int. 2007 Mar;71(5):376-9. doi: 10.1038/sj.ki.5002138.
Hyperphosphatemia is a prevalent condition in the dialysis population and is associated with bad outcome. Block et al. present data from a post hoc analysis indicating that sevelamer, a noncalcium-containing phosphate binder, may confer a survival benefit in incident hyperphosphatemic hemodialysis patients. This is the first intervention study in the field of mineral metabolism showing a beneficial effect on a hard end point.
高磷血症在透析人群中普遍存在，且与不良预后相关。布洛克等人展示了一项事后分析的数据，表明司维拉姆（一种不含钙的磷结合剂）可能对初发高磷血症血液透析患者有生存获益。这是矿物质代谢领域首个显示对硬终点有有益作用的干预性研究。
